logo-loader
viewMereo BioPharma Group PLC

Mereo BioPharma CEO confident as it moves forward with pivotal Setrusumab study

Mereo BioPharma's (LON:MPH) Denise Scots-Knight explains why she's confident in the potential of their lead drug setrusumab despite it not meeting its primary endpoint in a recent Phase 2b study.

The drug's being developed as a treatment for osteogenesis imperfecta which is also known as brittle bone disease.

Quick facts: Mereo BioPharma Group PLC

Price: 31 GBX

AIM:MPH
Market: AIM
Market Cap: £38.6 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Co-Diagnostics expects to win a CE mark-validated...

Co-Diagnostics Inc (NASDAQ:CODX) CEO Dwight Egan tells Proactive the Utah-based company expects to achieve a CE mark validation on its coronavirus detection test from the European Union by as early as next week. Egan says the company is very enthused by the entire process of the development...

1 day, 3 hours ago

2 min read